Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXFM244 in Moderate to Severe Rosacea
NCT01134991Phase 2Terminated
- Sponsor
- Vyne Therapeutics
- Start
- Jun 2010
- Primary completion
- Mar 2014
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zilxi in rosacea, sponsored by Vyne Therapeutics. Started Jun 2010; status: terminated.
02
Drugs
zilxi
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT01134991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01134991.